EMT6 Cells
CAD$545.10*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The EMT6 cell line is a murine mammary adenocarcinoma line that is extensively used in cancer research, particularly in studies related to breast cancer. Originating from a spontaneous tumor in a BALB/c mouse, EMT6 cells are employed both in vitro and in vivo to analyze tumorigenesis, metastasis, and chemotherapeutic resistance. The cells are characterized by their ability to form tumors rapidly when transplanted into immunocompetent mice, making them an ideal model for studying tumor immunity and the efficacy of anti-cancer therapies. EMT6 cells are highly adaptable to various growth conditions and have a relatively high mitotic index, which facilitates easy cultivation and experimental manipulation in laboratory settings. They are also used in radiobiology studies due to their pronounced sensitivity to radiation, providing insights into the cellular mechanisms underlying radiation therapy for cancer. The cell line has been instrumental in the development of protocols for hypoxic cell sensitizers and has been used to test the efficacy of photodynamic therapy agents. |
|---|---|
| Organism | Mouse |
| Tissue | Breast |
| Disease | Malignant neoplasms of the mouse mammary gland |
| Synonyms | EMT-6, Experimental Mammary Tumour-6 |
Characteristics
| Breed/Subspecies | BALB/cCRGL |
|---|---|
| Gender | Female |
| Morphology | Epithelial |
| Growth properties | Adherent |
Regulatory Data
| Citation | EMT6 (Cytion catalog number 305159) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 10090 |
| CellosaurusAccession | CVCL_1923 |
Biomolecular Data
Handling
| Culture Medium | DMEM:Ham's F12 (1:1), w: 3.1 g/L Glucose, w: 2.5 mM L-Glutamine, w: 15 mM HEPES, w: 0.5 mM Sodium pyruvate, w: 1.2 g/L NaHCO3 (Cytion article number 820400a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | Accutase |
| Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305159-130323SF | Certificate of Analysis | 23. May. 2025 | 305159 |
| 305159-190525 | Certificate of Analysis | 21. Jul. 2025 | 305159 |
| 305159-130323 | Certificate of Analysis | 23. May. 2025 | 305159 |